IJR News — today's news from every side

IJR News — today's news from every side

blockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

Loading

Genius — OpenServe

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

OpenServe Drive OpenServe Inbox OpenServe Write OpenServe Studio OpenServe Projects OpenServe Focus OpenServe Mindmaps Teams OpenServe CRM Site Builder Whiteboard

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

News

Home
Popular
Elections

Genius — OpenServe

Ivonescimab Cuts Death Risk 27% in NSCLC TrialHealth — Sep 13, 2026Ivonescimab significantly extends overall survival versus pembrolizumab in first-line PD-L1-positive advanced NSCLC, with a median OS of 30.8 months versus 22.6 months and a 27% reduction in death risk (HR 0.73). Benefits persisted across key subgroups, including PD-L1 high and squamous disease, and are driving international expansion through the ongoing HARMONi-7 study.

Nanobiotix Reports 79% Locoregional Control in Recurrent Lung Cancer Trial — Sep 14, 2026Nanobiotix's updated Phase 1 data for JNJ-1900 (NBTXR3) in inoperable, locoregionally recurrent NSCLC show no dose-limiting toxicities and a feasible intratumoral injection, with one-year results of 79% locoregional control, 61% LPFS, and 70% OS achieved at a lower re-irradiation dose. The findings reinforce the hafnium oxide nanoparticle–based radiosensitizer's potential to enable safe retreatment and spur further enrollment in dose-escalation and expansion cohorts.

Sam Okafor The fact that it works with lower re-irradiation doses could mean fewer side effects for patients facing this again.